Themis MedicareBOM:530199 +0.30%74 Pretax Margin % is 11.83% as of Mar. 2026, which is 2% above its 10-year median of 11.60. GuruFocus rates BOM:530199 with a GF Score™ of 74/100 and a GF Value™ of ₹149.02 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 961 Drug Manufacturers companies, Themis Medicare ranks worse than 65.97% on this metric.
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Themis Medicare Pretax Margin % Related Terms
Themis Medicare Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Themis Medicare's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:530199 vs ZTS, UTHR: Pretax Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Themis Medicare's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Themis Medicare Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Themis Medicare's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Themis Medicare's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Themis Medicare (BOM:530199) has a Pretax Margin % of 11.83% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Themis Medicare and its competitors. This is near median its historical median of 11.60. According to the industry distribution chart, Themis Medicare ranks #634 out of 961 companies in the Drug Manufacturers industry, placing it in the top 66%.
Is Themis Medicare's Pretax Margin % too high?
Themis Medicare's current Pretax Margin % of 11.83% is near median its 10-year median of 11.60. The Drug Manufacturers industry median Pretax Margin % is 7.28. Themis Medicare's value of 11.83% is 62.5% above this industry median. Based on the distribution chart, Themis Medicare ranks #634 out of 961 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Themis Medicare has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Themis Medicare's Pretax Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Themis Medicare ranks #634 out of 961 companies for Pretax Margin %. This places Themis Medicare in the lower half of its industry. The industry median Pretax Margin % is 7.28. Themis Medicare's value of 11.83% is 62.5% above this benchmark. While the company's 10-year median is 11.60 vs. the industry median of 7.28, Themis Medicare has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.28, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Themis Medicare's current Pretax Margin % of 11.83% is 62.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Themis Medicare and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Themis Medicare's current Pretax Margin % is 11.83%, which is near median its own 10-year median of 11.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Themis Medicare stock overvalued right now?
Based on GuruFocus' analysis, Themis Medicare (BOM:530199) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹149.02, compared to a current price of ₹117.00 — trading 21.5% below its estimated fair value. The current Pretax Margin % is 11.83%, which is near median its 10-year median of 11.60 and 62.5% above the Drug Manufacturers industry median of 7.28. Themis Medicare's overall GF Score™ is 74/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Themis Medicare (BOM:530199), the current Pretax Margin % is 11.83% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Themis Medicare (BOM:530199) Overvalued in 2026?
Based on GuruFocus' analysis, Themis Medicare stock appears to be undervalued.
The current stock price of ₹117.00 is trading 21.5% below its estimated GF Value™ of ₹149.02.
GuruFocus considers Themis Medicare to be Modestly Undervalued.
Key valuation signals for BOM:530199:
Pretax Margin %: 11.83% (near median its 10-year median of 11.60)
GF Value™: ₹149.02 vs. price of ₹117.00 (21.5% below fair value)
Industry Position: 62.5% above the Drug Manufacturers median (#634 of 961)
No single metric tells the full story. See the BOM:530199 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Themis Medicare Ltd is an Indian based company engaged in the manufacturing and marketing of pharmaceutical products. The Company operates only in one business segment which is Pharmaceuticals. Geographically, it derives a majority of revenue from India and also has a presence in the international market. Its product categories include Anti Malarial, CCD products, Nutritional Gummies, and Candy and Other Products such as OD-LM, Dexem, Medzol and Tazowin.
74GF Score
Get the complete analysis for BOM:530199
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:530199 has been successfully added to your 
